Ingredion Incorporated reported a 26% decline in reported EPS to $2.22 in Q1 2026, mainly due to operational challenges at its Argo facility affecting the U.S./Canada segment. Despite this, other segments like Texture & Healthful Solutions showed steady growth. The company lowered its full-year 2026 EPS guidance to a range of $9.60 to $10.30, citing ongoing operational headwinds and macroeconomic uncertainties. Ingredion expects gradual improvement in operations in the second half of the year and continues to focus on innovation and customer service.
Silvaco and NVIDIA have teamed up to enhance semiconductor design and manufacturing by integrating NVIDIA's AI and accelerated computing with Silvaco's physics-based simulation technology. This collaboration aims to create high-fidelity digital twins...
Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, was ranked No. 3 on The Medicine Maker Power List 2026 in the Small Molecules category, recognizing his leadership in oncology drug development. Under his guidance, Ascentage Pharma has advanced i...
BYD, a leading new energy vehicle manufacturer, has partnered with Smart, Australia's top salary packaging and novated leasing provider, to make electric vehicles (EVs) more accessible and affordable for Australians. This partnership allows eligible ...
Chinese chipmaker Changxin Technology Group (CXMT) saw its shares surge about 470% on their debut at Shanghai's STAR Market after raising $8.6 billion in its IPO. The Hefei-based company holds a 7.67% share of the global DRAM market as of 2025 and pl...
Circle's shares have fluctuated between $60 and $75 as the company gained OCC approval to establish Circle National Trust, enhancing its regulatory status and digital-asset banking capabilities. This regulatory milestone strengthens Circle's position...
